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an organ or region, the average dose received therein. Comparing the results obtained in the three types of treatment for three
rings around the prostate or LQ at a distance of 1, 2 and 5 cm and a thickness of 2mm, integral dose less the overall volume PTV.
The latter were obtained V2, V5, V10, V20 and V30 assess areas of low doses. Were noted (UM) necessary to provide a dose of
2Gy per session in each case. We performed a Wilcoxon test to compare the results of IMRT and VMAT treatments with 3DCRT,
the statistical threshold was p≤0.05. The tests and statistical analyzes were performed with SPSS.
Results and discussion. Compared with 3D planning, IMRT has half integral dose values lower for all regions, the difference was
statistically signiﬁcant in all cases (p≤0.05). Volumes of low-dose behavior is the same, are lower in IMRT than 3DCRT. In the
comparison between 3D andVMAT, half full dose is greater VMAT, signiﬁcant difference in the case of prostate, and not signiﬁcant
for the LQ (p>0.05). In the low dose volume is more complex, but the greater the VMAT V10, V20 and V30 in the LQ, which are
less. Average number of UM necessary in IMRT is much higher than the other techniques, which should be taken into account
by its relation to radiation leakage, reaching, in the case of LQ, to double that of 3DCRT (3DCRT, 362; IMRT, 731; VMAT, 472).
Conclusions. IMRT technique presents comprehensive dose reduction in healthy tissue, decreasing volumes irradiated at low
doses, however, the number of monitor units increased almost double, which should be taken into account by radiation leak.
VMAT presents integral generally higher dose and low-dose irradiated volume that the standard technique in the treatment of
prostate, not be so in the case of LQ.
http://dx.doi.org/10.1016/j.rpor.2013.03.604
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Introduction. In 2011, Centro Oncológico de Galicia (COG) clinically introduced RapidArc® (Varian Medical Systems) as a new
radiation delivery technique for Volumetric Modulated Arc Therapy (VMAT). Purpose/objective: We will show our RapidArc®
implementation experience as well as a summary of statistics of patients treated with RapidArc technique at COG in the ﬁrst 2
years from its clinical implementation.
Materials and methods. Since 2011, about 350 patients were planned for RapidArc® including head and neck, prostate, pelvis with
lymph nodes, stereotactic lung, cranio-spinal irradiation, etc. All plans were generated using Varian Eclipse Treatment Planning
System (TPS) and delivered by a Varian Clinac DHX with MLC120 and on-board imager for image guidance. Pre-treatment quality
assurance (QA) is performed by measuring the absolute planar dose distribution in the PTW Octavius and ArcCheck phantoms,
in addition Portal Dosimetry is employed for QA.
Results. RapidArc delivery utilizes fewer monitor units (MUs) and is considerably faster than the corresponding Intensity Mod-
ulated Radiotherapy (IMRT) treatment plan while preserving treatment plan quality. Shorter treatment times have obvious
advantages including better patient throughput, improved patient comfort and, possibly, less intra fractional motion. Aver-
age segmental ﬁeld size or MLC leaf opening is much larger for RapidArc than Sliding Window IMRT, so RapidArc deliveries
were expected to be more tolerant to variations in gantry rotation and MLC leaf position. Although the portal dosimetry was
successfully validated,we are reluctant to use it as a solemeans of patientQAas long as no gantry angle information is embedded.
Conclusions/discussion. RapidArc provided a signiﬁcant sparing of OARs and healthy tissue without compromising target coverage
compared to IMRT, with excellent results in difﬁcult geometry target volumes. Since RapidArc was introduced in clinical practice,
results are conﬁrming expectations and the new modality has progressively replaced IMRT in most of the clinical indications at
COG.
http://dx.doi.org/10.1016/j.rpor.2013.03.605
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Several publications have proposed during the last years hypofractionated treatment schedules in prostate cancer. Ratio for
prostate carcinoma /. Such schedules have been possible because this comparable to, and even lower than, the surrounding
late-responding normal tissues. This work shows the scheme adopted in our institution for hypofractionated prostate cancer
treatment and plan evaluation based in DVH parameters. Monaco 3.10 (CMS, Elekta) is the inverse planning system used for volu-
metric arc therapy (VMAT). Treatments are delivered with an Elekta Synergy linac. Daily cone-beam CT corrections are performed
as image-guided radiation=/ therapy technique. The fractionation schedule, with the assumption that 1.5Gy for targets and
3.0Gy forOARs, consists on 28 fractions, delivering 2.5Gy to prostate gland, 2.0Gy to seminal vesicles and 1.8Gy if lymphnodes are
included. Dose–volume constraints are taken from QUANTEC reviews and they are adapted to our fractionation scheme accord-
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ing the linear-quadratic model ratios): V45.4/ (assuming the previous<50%, V54.5 < 35%, V59.0 < 25%, V63.6 < 20%, V68.2 < 50%
for rectum; V59.0 < 50%, V63.6 < 35%, V68.2 < 25%, V72.7 < 15% for bladder; Dmax<45.4Gy for femoral heads; Dmean<45.4Gy for
penile bulb. Valid singleVMATarcplans are generatedby theTPS. Target volumespreserve theoptimalhomogeneity andcoverage,
as well as OARs maintain their dose–volume parameters under those imposed by QUANTEC: 3.1)%, ±4.0)%, V63.6 = (6.5±4.4)%,
V59.0 = (8.9±5.9)%, V54.5 = (11.7±V45.4 = (20.3 6.5)%,±7.3)%, V63.6 = (9.5±2.4)% for rectum; V59.0 = (12.2±V68.2 = (4.1 4.6)Gy for
femoral±4.0)% for bladder; Dmax= (35.3±5.6)%, V72.7 = (2.7±V68.2 = (6.5 3.7) Gy for penile bulb. Mean treatment time is 310±43
s.±heads; Dmean= (42.3 VMAT in conjunction with IGRT techniques are powerful tools to cover a hypofractionated prostate
cancer treatment program. It is possible to generate optimal plans to treat target volumes as well as to accomplish QUANTEC
constraints. VMAT treatment technique allows the delivery of the treatment in a single arc, with a signiﬁcant reduction in
treatment time.
http://dx.doi.org/10.1016/j.rpor.2013.03.606
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Introduction. The National Radiotherapy Advisory Group (NRAG) of the U.K. recommended that 24% of all radical fractions (32%
of patients) should be delivered with inverse planned IMRT as target for quality radiotherapy care indicator.1
Objective. To analyse the inverse planned IMRT (IP-IMRT) pattern in our center and compare the results to the NRAG recommen-
dations.
Patients & methods. The radiation oncology unit at Alcazar de San Juan covers a population of 203.233 in-habitants censored in
2011. From Jan to Dec 2011 a total of 344 patients were referred for radiation therapy, 106 of these with palliative intent and were
excluded as IP-MRT was not used for palliation.
Results. 36.9% of patients (88 out of 238) received IP-IMRT with radical intent (deﬁne as exclusive & pre or postoperative radiothe-
rapy), accounting for 31.7% of the total number of fractions administered. The technique used was hypofractionated SIB-IMRT in
71.5% of pts and a standard fraction one phase IMRT in 27.3%. According to primary tumor localization the IP-IMRT distribution
was: Prostate 42%, rectal cancer 32% (SIB-IMRT dose escalation study), HNC 15%, Gynecologic cancers 8%. The IMRT use by tumor
site was: Proste 100%, Rectal 82%, HNC 76%, Gynecol 77%. Distribution by treatment intention was as follows: RT only 34.5%,
preoperative 32%, postoperative 23%, cancer local relapse 11%.
Conclusion. Use of IP-IMRT in our center is quite similar to the NRAG recommendations and greater than the 9.9% (8.5% IP-
IMRT+1.4%VMAT) of a recent survey in theUK2 or the 6.2%use in France.3 This benchmarking study allowsus future comparisons
in changing scenarios as reimbursement modiﬁcations or economical constraints.
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Purpose. Keloid represents a signiﬁcant bother for patients and a therapeutic challenge. We present adjuvance with electron
therapy after surgical excision with curative intention.
Materials and methods. Since May – 2007, we treated 20 keloids in 19 patients. Mean age was 38.5 years (interval 16–80). Twelve
females and 8 males were irradiated with a maximum of 4h after surgery. The radiotherapy was delivered using a Clinac 2100
(Varian MS-Palo Alto). Beam energy was 6MeV, with a 4-mm thick aluminum foil 4-mm thick covering the end of the electron
applicator, used as a spoiler. Doses of 15Gy in 5 fractions of 300 cGy/d. were delivered. A 0.5 cm margin around the surgery
excision was included within the treatment ﬁeld, taking account that a thin lead mold should be placed around the scar on the
skin, at least 1 cm inside the optical ﬁeld in order to reduce the beam penumbra. To evaluate results and impact a photograph
was taken before surgery and at the beginning of therapy, and also every year during the follow up (follow-up interval: 4–68
months).
